University of Miami and Starx Therapeutics Inc. have presented data on UMF-814A, a STK17A inhibitor with promising activity in myelodysplastic syndrome and acute myeloid leukemia.
Researchers from Jacobio Pharmaceuticals Co. Ltd. recently presented preclinical data on JAB-BX600, an EGFR-directed antibody-drug conjugate (ADC) that selectively delivers a KRAS G12D inhibitor to tumor cells, allowing dual inhibition of the EGFR-KRAS pathway.
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological imprint. At the 26th International AIDS Conference (AIDS 2026), researchers reported persistent abnormalities affecting the gut, cardiovascular system, metabolism and immune function despite effective viral control.
Taiwan’s biotechnology sector was built around domestic health needs, including vaccines and drug manufacturing, but it is increasingly looking outward – to international partnerships, licensing, clinical development and a bigger role in the global biomedical ecosystem.
Taiwan’s biotechnology sector was built around domestic health needs, including vaccines and drug manufacturing, but it is increasingly looking outward – to international partnerships, licensing, clinical development and a bigger role in the global biomedical ecosystem.
At the American Association for Cancer Research’s inaugural Drug Discovery and Development conference (AACR D3), Onconano Medicine Inc. presented preclinical data on ONM-421, a pH-responsive polymer-drug conjugate nanoparticle developed using the company’s proprietary ON-BOARD platform.
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that can demonstrate clinical differentiation, strong management teams and a clear path to commercialization.
The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell therapeutics emerging as the dark horse in what speakers at BIO Asia-Taiwan 2026 described as CAR T’s second revolution.
The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell therapeutics emerging as the dark horse in what speakers at BIO Asia-Taiwan 2026 described as CAR T’s second revolution.
The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell therapeutics emerging as the dark horse in what speakers at BIO Asia-Taiwan 2026 described as CAR T’s second revolution.
RSS
